Donor-derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response

Br J Haematol. 2014 Jul;166(2):209-12. doi: 10.1111/bjh.12847. Epub 2014 Mar 25.

Abstract

Donor-derived myelodysplastic syndrome/acute leukaemia (DD-MDS/AL) is a rare life-threatening complication of allogeneic haematopoietic stem cell (HSC) transplantation. However, it is unknown whether the risk differs by HSC source. Therefore, we evaluated the incidence of DD-MDS/AL in 2390 engrafted patients. With a median follow-up of 7·1 years (1-20·8), the incidence of DD-MDS/AL was 0·53% (95% confidence interval (CI), 0·01-1·41%], 0·56% (95%CI, 0·01-1·36%) and 0·56% (95%CI, 0·01-1·10%) in recipients of bone marrow (n = 1117), peripheral blood (n = 489) and umbilical cord blood (UCB, n = 784), respectively. While follow-up is shorter in recipients of UCB and peripheral blood, incidence of DD-MDS/AL is, thus far, similar between HSC sources.

Keywords: donor-derived leukaemia; haematopoietic cell transplantation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Child
  • Female
  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Hematopoietic Stem Cell Transplantation / methods
  • Humans
  • Incidence
  • Leukemia / epidemiology
  • Leukemia / etiology*
  • Leukemia / therapy
  • Male
  • Middle Aged
  • Minnesota / epidemiology
  • Myelodysplastic Syndromes / epidemiology
  • Myelodysplastic Syndromes / etiology*
  • Myelodysplastic Syndromes / therapy
  • Tissue Donors*
  • Treatment Outcome
  • Young Adult